Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Net Income towards Common Stockholders fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.36% down from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Net Income towards Common Stockholders is -$19.7 million, which was up 35.02% from -$30.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $35.8 million for Q3 2024, and its period low was -$112.4 million during Q2 2024.
  • In the last 3 years, Day One Biopharmaceuticals' Net Income towards Common Stockholders had a median value of -$44.3 million in 2023 and averaged -$43.4 million.
  • Within the past 5 years, the most significant YoY rise in Day One Biopharmaceuticals' Net Income towards Common Stockholders was 177.66% (2024), while the steepest drop was 165.16% (2024).
  • Quarterly analysis of 3 years shows Day One Biopharmaceuticals' Net Income towards Common Stockholders stood at -$54.5 million in 2023, then declined by 20.61% to -$65.7 million in 2024, then slumped by 154.94% to -$19.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$19.7 million in Q3 2025, compared to -$30.3 million in Q2 2025 and -$36.0 million in Q1 2025.